PureTech Health (PRTC)
NASDAQ:PRTC
Top Page
PureTech Health
(NASDAQ:PRTC)
Select Model
Select Model
Rating:55Neutral
Price Target:
$19.50
▲(10.92% Upside)
Action:ReiteratedDate:11/19/25
PureTech Health's overall stock score reflects a mixed financial performance with a strong balance sheet but operational inefficiencies. Technical analysis indicates bearish momentum, while valuation suggests potential undervaluation. The earnings call provided a balanced outlook with strong cash reserves but highlighted challenges in external financing and leadership transitions.
Positive Factors
Strong cash position
A cash balance near $320M provides a durable runway to fund discovery and founded entities, reducing immediate refinancing pressure. This liquidity supports multi-year clinical programs and strategic capital allocation, allowing PureTech to execute development plans and pursue value-creating exits.
Negative Factors
External funding reliance
Core founded entities depend on continued external financings to progress trials. This structural reliance risks dilution, timing delays, or suboptimal deal terms if capital markets tighten, and it constrains PureTech's control over development pacing and potential returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash position
A cash balance near $320M provides a durable runway to fund discovery and founded entities, reducing immediate refinancing pressure. This liquidity supports multi-year clinical programs and strategic capital allocation, allowing PureTech to execute development plans and pursue value-creating exits.
Read all positive factors
PureTech Health (PRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$399.15M
Dividend YieldN/A
Average Volume (3M)4.02K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth1268.81%
EPS GrowthN/A
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.90
Shares Outstanding24,341,820
10 Day Avg. Volume1,390
30 Day Avg. Volume4,023
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.20
Price to Sales (P/S)103.10
P/FCF Ratio-3.70
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue33.23
Enterprise Value/Gross Profit9.81
Enterprise Value/Ebitda3.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.47
Revenue Forecast (FY)$49.50M
PureTech Health Business Overview & Revenue Model
Company Description
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological...
How the Company Makes Money
PureTech Health generates revenue through several key streams, including licensing agreements, collaborations, and equity stakes in its pipeline companies. The company often partners with larger pharmaceutical firms to co-develop its products, whi...
PureTech Health Earnings Call Summary
Earnings Call Date:Aug 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted PureTech's strong cash position and operational efficiency, progress in core founded entities, and strategic financing with promising valuation for Seaport Therapeutics. However, there are challenges with the need for ongoing external financing for core entities and leadership transitions. The overall sentiment is balanced with strong positive aspects but also significant challenges.Positive Updates
Strong Cash Position and Operational Efficiency
PureTech ended the half year with just under $320 million in cash, cash equivalents, and short-term investments. Operating expenses reduced from $66.7 million in the same period last year to just under $50 million, demonstrating efficient operations.
Negative Updates
Dependence on External Financing for Core Entities
Celea Therapeutics and Gallop Oncology require external funding to advance their programs, leaving some uncertainty about future financing structures and potential dilution.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Cash Position and Operational Efficiency
PureTech ended the half year with just under $320 million in cash, cash equivalents, and short-term investments. Operating expenses reduced from $66.7 million in the same period last year to just under $50 million, demonstrating efficient operations.
Read all positive updates
Company Guidance
During the PureTech Health 2025 Half Year Earnings Webcast, the company provided guidance focusing on three key strategic pillars: developing new treatments with patient-centered urgency, strengthening engagement with U.K. capital markets, and maintaining a disciplined capital allocation approach. PureTech highlighted its promising lead program, deupirfenidone (LYT-100), significant progress in clinical trials, and the potential to deliver long-term value for patients and shareholders. The company also discussed its hub-and-spoke model, exemplified by the success of Karuna Therapeutics, which involved an $18.5 million initial investment leading to a significant financial return. Additionally, PureTech announced plans to appoint up to two new nonexecutive directors to strengthen its board with U.K. capital markets expertise. The interim CEO, Robert Lyne, emphasized their focus on operational discipline and leveraging external capital to fund new entities like Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics, aiming to extend the operational runway well into 2028 with a strong cash position of just under $320 million.PureTech Health Financial Statement Overview
Summary
Income Statement
40
Negative
Balance Sheet
55
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.88M | 4.83M | 3.33M | 2.09M | 9.98M | 8.34M |
| Gross Profit | 19.91M | 1.26M | -1.60M | -136.81M | -100.49M | 8.34M |
| EBITDA | 55.73M | 37.38M | -11.63M | -188.91M | 26.70M | 62.69M |
| Net Income | 50.68M | 53.51M | -65.70M | -50.35M | -60.56M | 5.99M |
Balance Sheet | ||||||
| Total Assets | 553.24M | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 321.55M | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 20.92M | 22.36M | 25.34M | 46.87M | 52.75M | 76.62M |
| Total Liabilities | 184.22M | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 375.98M | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | ||||||
| Free Cash Flow | -100.31M | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -100.30M | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 31.89M | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | 18.51M | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
Positive
17.58
Price Trends
16.91
Positive
17.07
Positive
17.37
Positive
Market Momentum
-0.10
Negative
66.59
Neutral
86.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTC, the sentiment is Positive. The current price of 17.58 is above the 20-day moving average (MA) of 15.87, above the 50-day MA of 16.91, and above the 200-day MA of 17.37, indicating a bullish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 66.59 is Neutral, neither overbought nor oversold. The STOCH value of 86.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $456.00M | -4.14 | -59.68% | ― | -33.09% | 3.38% | |
55 Neutral | $399.15M | -2.27 | 12.82% | ― | 1268.81% | ― | |
52 Neutral | $500.82M | -3.10 | -47.27% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $396.55M | -1.84 | -99.00% | ― | 407.86% | 30.35% | |
47 Neutral | $475.15M | -3.14 | 76.03% | ― | 6.35% | 39.57% |
* Healthcare Sector Average
PRTC
PureTech Health
17.81
0.95
5.67%
AUTL
Autolus Therapeutics
1.47
0.07
5.00%
ADCT
ADC Therapeutics
3.81
2.60
214.88%
FDMT
4D Molecular Therapeutics
10.04
6.94
223.87%
ABSI
AbSci
3.05
-0.07
-2.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.